Allogeneic cell therapy does not improve short-term outcomes in acute ischemic stroke

For older adults with acute ischemic stroke, IV administration of an allogeneic cell therapy within 18 to 36 hours of onset was found to be safe but did not improve short-term outcomes, researchers reported in JAMA Neurology. 
“Evidence-based reperfusion therapies, including intravenous thrombolysis and mechanical thrombectomy, are widely used for stroke treatment,” Kiyohiro Houkin, MD, of Hokkaido University in Japan, and colleagues wrote. “This dynamic landscape highlights the need for new treatment options and expansion of the therapeutic window.”
Houkin and fellow

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.